Reflect the true value of your therapy with
Patient-Centered Research Solutions for Life Sciences
Chroma provides the most granular measurement of patients’ longitudinal experiences & outcomes, captured where life happens:
Tracking data from real user “Emily” (renamed)
Without Folia, our user Emily would have generated clinical data on only 5 days in 2019.
With Folia, Emily generated a structured dataset that captured what happens between clinic visits, including:
Flares/Acute events, and resolutions
Non-standard symptoms
Treatment use, or reasons for non-use
With decreased recall bias and the ability to capture only the outcomes that matter to her.
Uniquely designed to maximize flexibility
and create phenomenal participant experiences:
A disease-agnostic platform supporting 500+ conditions:
Patients and caregivers use Folia Health to track daily experiences across:
Autoimmune conditions
Neurological, psychiatric and behavioral conditions
Genetic and rare conditions
Cancer and hematology
Chronic and more
Sponsors provide day-to-day value to participants:
Users e-consent into prospective outcomes studies, and get compensated for participation.
Study data is immediately available for participant use with their care team.
And once the study is complete, patients continue to track on Folia - for free, for life.
A suite of patient-driven outcomes solutions built for life sciences,
from early clinical development to therapy commercialization:
Natural History
Burden
Impact
How Chroma works
Comprehensive, end-to-end research solution for complex, heterogeneous conditions:
Dedicated research and analysis team
Protocol design & approval
Multi-channel recruitment, e-consent, enrollment
Validated ePRO deployment that complements HROs
Data stewardship & hosting
Linkage to EMR, claims, wearables, and registry data
Data analysis and reporting
Thought partnership for scientific communications and publications
Customer Perspectives:
My programs often struggle with the fact that traditional clinical endpoints do not demonstrate the full value of the therapy, and we experience a disconnect about endpoints needed for Approval vs. for Reimbursement.
Vice President, HEOR (Neurology Biotech)
This gives you insight that you don’t get from PROs and does not rely on long recall period. To me, that is the interesting nuance.
Executive Director, WW HEOR RWD (Top 10 Pharma)
Why Life Sciences Innovators Choose Folia
Solve common RWD dataset challenges:
Identify, characterize, and measure change in currently undetected flare events
Measure disease heterogeneity and discover phenotypes that drive how patients do on therapy
Understand treatment use, including “Why not?” reasons and missing doses/switching medications
Patient-driven, high fidelity, and high value insights:
Discover the full scope of patient priorities & how your therapy impacts them
Reduce responder burden with questions that are relevant to each participant’s journey
Drive value to the patient with built-in patient data return
